Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00899405 |
Recruitment Status :
Recruiting
First Posted : May 12, 2009
Last Update Posted : February 7, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.
Condition or disease |
---|
Lung Cancer |
OBJECTIVES:
- Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
- Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.
OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.
Study Type : | Observational |
Estimated Enrollment : | 800 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood |
Study Start Date : | May 2005 |
Estimated Primary Completion Date : | December 2022 |
Estimated Study Completion Date : | June 2023 |

Group/Cohort |
---|
Patients with lung cancer
Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
|
- Mutational status of the EGFR pathway [ Time Frame: up to 1 year ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed lung cancer
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- May have received prior EGFR inhibitors

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899405
United States, California | |
University of California Davis Cancer Center | Recruiting |
Sacramento, California, United States, 95817 | |
Contact: Clinical Trials Office - University of California Davis Cancer 916-734-3089 |
Principal Investigator: | Philip C. Mack, PhD | University of California, Davis |
Responsible Party: | University of California, Davis |
ClinicalTrials.gov Identifier: | NCT00899405 |
Other Study ID Numbers: |
225287 UCD-155 UCD-200412410 CDR0000583056 ( Other Identifier: UCD ) |
First Posted: | May 12, 2009 Key Record Dates |
Last Update Posted: | February 7, 2022 |
Last Verified: | January 2022 |
lung cancer |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |